Overview

Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

Status:
Recruiting

Trial end date:
2022-02-02

Target enrollment:

Participant gender:

Summary

- the change of sitSBP based on baseline between Treatment arm and control 1 arm [ Time Frame: 8 weeks ] - the change of LDL-C based on baseline between Treatment arm and control2 arm [ Time Frame: 8 weeks ]

Phase:

Phase 3

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Amlodipine
Amlodipine Besylate, Olmesartan Medoxomil Drug Combination
Ezetimibe
Olmesartan
Olmesartan Medoxomil
Rosuvastatin Calcium